Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + dexamethasone in relapsed/refractory RAS-pathway mutated paediatric and adult ALL
NL-OMON55542Phase 2Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selumetinib and dexamethasone in acute lymphoblastic leukemia (ALL), sponsored by University of Birmingham. Primary endpoints: Recommended phase II dose selection and Response rate. Started Jan 2021; status: active, not recruiting.
02
Drugs
selumetinibdexamethasone
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON55542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55542.